Patents by Inventor Mark Stuart Chambers

Mark Stuart Chambers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HTT modulators for treating Huntington's disease
    Patent number: 11806346
    Abstract: Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: November 7, 2023
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Elizabeth M. Doherty, Longbin Liu, Matthew Lee, Mark Stuart Chambers, Karine Fabienne Malagu, Perla Breccia, Alan F. Haughan, Huw D. Vater, Andrew J. Stott, William R. K. Esmieu, Stephen John Webster, Amanda J. Van De Poël
  • HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20220409615
    Abstract: Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.
    Type: Application
    Filed: May 12, 2021
    Publication date: December 29, 2022
    Inventors: Celia Dominguez, Elizabeth M. Doherty, Longbin Liu, Matthew Lee, Mark Stuart Chambers, Karine Fabienne Malagu, Perla Breccia, Alan F. Haughan, Huw D. Vater, Andrew J. Stott, William R. K. Esmieu, Stephen John Webster, Amanda J. Van De Poël
  • Amino-substituted heterocyclic derivatives as sodium channel inhibitors
    Patent number: 10214509
    Abstract: The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: February 26, 2019
    Assignee: Almirall, S.A.
    Inventors: James Duffy, Mark Stuart Chambers, Alastair Rae, James Osborne, Isabelle Anne Lemasson, Michael Daniel Goldsmith, Andrew Sharpe, Silvia Fonquerna Pou
  • FUSED IMIDAZOLE COMPOUNDS
    Publication number: 20180289718
    Abstract: The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA ?5) and act as GABAA ?5 negative allosteric modulators (GABAA ?5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA ?5 such as Alzheimer's disease.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuji SAITO, Masato HIGASHINO, Soichi KAWAHARADA, Arwel LEWIS, Mark Stuart CHAMBERS, Alastair RAE, Kim Louise HIRST, Charles David HARTLEY
  • Fused imidazole compounds
    Patent number: 10016439
    Abstract: The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA ?5) and act as GABAA ?5 negative allosteric modulators (GABAA ?5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA ?5 such as Alzheimer's disease.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: July 10, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuji Saito, Masato Higashino, Soichi Kawaharada, Arwel Lewis, Mark Stuart Chambers, Alastair Rae, Kim Louise Hirst, Charles David Hartley
  • AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS
    Publication number: 20180105509
    Abstract: The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives.
    Type: Application
    Filed: April 20, 2016
    Publication date: April 19, 2018
    Inventors: James DUFFY, Mark Stuart CHAMBERS, Alastair RAE, James OSBORNE, Isabelle Anne LEMASSON, Michael Daniel GOLDSMITH, Andrew SHARPE, Silvia FONQUERNA POU
  • FUSED IMIDAZOLE COMPOUNDS
    Publication number: 20160331757
    Abstract: The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA ?5) and act as GABAA ?5 negative allosteric modulators (GABAA ?5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA ?5 such as Alzheimer's disease.
    Type: Application
    Filed: January 30, 2015
    Publication date: November 17, 2016
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuji SAITO, Masato HIGASHINO, Soichi KAWAHARADA, Arwel LEWIS, Mark Stuart CHAMBERS, Alastair RAE, Kim Louise HIRST, Charles David HARTLEY
  • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 9006237
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: April 14, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Giovanni Alessandro Tricarico, Grégory Louis Joseph Bar, Kim Louise Hirst, Olga Raquel Pinto Santos Oliveira Roussel, Juha Andrew Clase
  • Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases
    Publication number: 20120232075
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 13, 2012
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Giovanni Alessandro Tricarico, Grégory Louis Joseph Bar, Kim Louise Hirst, Olga Raquel Pinto Santos Oliveira Roussel, Juha Andrew Clase
  • Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8178530
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: May 15, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus MacLeod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8173656
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: May 8, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus Macleod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8148369
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: April 3, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Giovanni Alessandro Tricarico, Grégory Louis Joseph Bar, Kim Louise Hirst, Olga Raquel Pinto Santos Oliveira Roussel, Juha Andrew Clase
  • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8138193
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: with Z, R1, R2, R8 and R9 as defined in the written description. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: March 20, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Grégory Louis Joseph Bar
  • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8133895
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: March 13, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Grégory Louis Joseph Bar
  • IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20110218178
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Application
    Filed: December 16, 2010
    Publication date: September 8, 2011
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus Macleod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8012983
    Abstract: Novel [1.2.4]triazolo[1,5-a]pyrazine and imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: September 6, 2011
    Assignee: Galapagos NV
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Hervé Van De Poël, Grégory Louis Joseph Bar
  • TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20110178067
    Abstract: Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.
    Type: Application
    Filed: January 9, 2011
    Publication date: July 21, 2011
    Inventors: Martin James Inglis Andrews, Paul Edwards, Mark Stuart Chambers, Wolfgang Schmidt, Juha Andrew Clase, Gregory Bar, Kim Louise Hirst, Angus Macleod
  • IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20110092497
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Application
    Filed: December 16, 2010
    Publication date: April 21, 2011
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus Macleod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 7915256
    Abstract: Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.
    Type: Grant
    Filed: March 8, 2009
    Date of Patent: March 29, 2011
    Assignee: Galapagos NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Mark Stuart Chambers, Wolfgang Schmidt, Juha Andrew Clase, Gregory Bar, Kim Louise Hirst, Angus MacLeod
  • Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 7893058
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: February 22, 2011
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus MacLeod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar